Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Earnings for Ocugen, Inc. (OCGN)
Earnings in 2023 (TTM): $-63,078,000
According to Ocugen, Inc.'s latest financial reports the company's current earnings (TTM) are $-63,078,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ocugen, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-63,078,000 | $-63,078,000 |
| 2022 | $-81,351,000 | $-77,834,000 |
| 2021 | $-58,417,000 | $-58,365,000 |
| 2020 | $-21,821,953 | $-22,623,468 |
| 2019 | $-20,242,630 | $-21,225,593 |
| 2018 | $-8,643,000 | $-8,643,000 |
| 2017 | $-26,414,000 | $-26,414,000 |
| 2016 | $-16,208,000 | $-16,208,000 |
| 2015 | $-32,024,000 | $-32,024,000 |
| 2014 | $-22,793,000 | $-22,793,000 |
| 2013 | $-25,712,000 | $-25,712,000 |
| 2012 | $-16,935,000 | $-16,935,000 |